Innovent Biologics is planning a second filing for its dual GLP-1/glucagon agonist mazdutide in China, as it tries to carve out a share of a market currently dominated by Novo Nordisk and E
Jacobio Pharma has reported the results of its pivotal Chinese study of KRAS G12C inhibitor glecirasib, with a safety profile that could differentiate it from other drugs
Sanofi is making a €300 million investment in Chinese biotech Innovent as part of a collaboration to bring two new cancer therapies as quickly as possible to patients in the world's second-
The FDA has dropped a bomb on Eli Lilly's marketing application for cancer immunotherapy sintilimab ahead of an advisory committee meeting due to take place on Thursday.
Eli Lilly made a late entry into the checkpoint inhibitor market when it licensed ex-China rights to Innovent's sintilimab last year, and a new trial in lung cancer will raise its hopes of
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl